Ambulatory treatment of acute myeloid leukemia (AML) with weekly oral idarubicin alone in poor-risk elderly patients.

被引：0
|
作者：
Anglaret, B
Belhabri, A
Chelghoum, Y
Renaudier, P
Troncy, J
Bouheddou, N
Peaud, PY
Chevalier, MP
Thomas, X
机构：
[1] Ctr Hosp, Valence, France
[2] Hop Edouard Herriot, Lyon, France
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4621
引用
收藏
页码：208B / 208B
页数：1
相关论文
共 50 条
  • [21] Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML
    Allen, Steven L.
    Erba, Harry P.
    Rizzieri, David A.
    O'Donnell, Margaret
    Powell, Bayard
    Lundberg, Ante S.
    Bennett, John M.
    Capizzi, Robert L.
    BLOOD, 2008, 112 (11) : 1019 - 1020
  • [22] Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia
    D. Russo
    P. Piccaluga
    M. Michieli
    T. Michelutti
    G. Visani
    L. Gugliotta
    A. Bonini
    I. Pierri
    M. Gobbi
    M. Tiribelli
    R. Fanin
    S. Piccolrovazzi
    M. Baccarani
    Annals of Hematology, 2002, 81 : 462 - 466
  • [23] Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients
    Hartmann, F
    Jacobs, G
    Gotto, H
    Schwamborn, J
    Pfreundschuh, M
    LEUKEMIA & LYMPHOMA, 2001, 42 (03) : 347 - 355
  • [24] Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly
    Kuendgen, Andrea
    Germing, Ulrich
    CANCER TREATMENT REVIEWS, 2009, 35 (02) : 97 - 120
  • [25] Treatment of elderly acute myeloid leukemia (AML) patients with the combination of mitoxantrone and cytarabine (MAC).
    Marinakis, T
    Galanopoulos, AG
    Zomas, A
    Michalis, E
    Gortzolidis, G
    Tsakiridou, A
    Xanthopoulos, V
    Theodoropoulos, G
    Goumakou, H
    Georgiakaki, M
    Grigoraki, V
    Anagnostopoulos, NI
    BLOOD, 2005, 106 (11) : 235B - 235B
  • [26] ORAL IDARUBICIN PLUS CYTOSINE-ARABINOSIDE IN THE TREATMENT OF ACUTE NONLYMPHOBLASTIC LEUKEMIA IN ELDERLY PATIENTS
    PAGANO, L
    SICA, S
    MARRA, R
    VOSO, MT
    STORTI, S
    DIMARIO, A
    LEONE, G
    HAEMATOLOGICA, 1991, 76 (06) : 517 - 518
  • [27] The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia
    Knapper, Steven
    HAEMATOLOGICA, 2015, 100 (09) : 1105 - 1107
  • [28] Perceptions of prognosis and treatment risk in older patients with acute myeloid leukemia (AML).
    Nicholson, Showly
    Abel, Gregory A.
    Fathi, Amir Tahmasb
    Steensma, David P.
    LeBlanc, Thomas William
    DeAngelo, Daniel J.
    Wadleigh, Martha
    Hobbs, Gabriela
    Foster, Julia
    Brunner, Andrew Mark
    Amrein, Philip C.
    Stone, Richard M.
    Temel, Jennifer S.
    El-Jawahri, Areej
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31)
  • [29] Improved Responses with Azacitidine Compared to Decitabine in Patients with Acute Myeloid Leukemia in Patients ≥70 with Poor-Risk Cytogenetics
    Talati, Chetasi
    Kuykendall, Andrew
    Al-Ali, Najla
    Komrokji, Rami
    Padron, Eric
    Sallman, David
    List, Alan
    Sweet, Kendra
    Extermann, Martine
    Lancet, Jeffrey
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S295 - S295
  • [30] The Effect of Decreased-dose Idarubicin for Elderly Patients with Acute Myeloid Leukemia
    Kobayashi, Takashi
    Ichikawa, Motoshi
    Nannya, Yasuhito
    Kurokawa, Mineo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (10) : 1047 - 1051
12345